QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.